Novel Rx
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
This included the following abstracts:
0025 Cannibinoids & pain
1584 TMP/SMX in GPA
0607 CAR-T cells in…
1 year 6 months ago
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
1 year 6 months ago
Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23
Feasible after early remission induction https://t.co/WwiNp8WKDC
1 year 6 months ago
Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer
.Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
1 year 6 months ago
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Poster Hall